Design, synthesis, structure, toxicology and in vitro testing of three novel agents for Alzheimer's disease
RSC Advances, ISSN: 2046-2069, Vol: 7, Issue: 38, Page: 23457-23467
2017
- 4Citations
- 6Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
This article describes the synthesis of three novel compounds for the treatment of Alzheimer's disease (AD). The compounds were formed by the reaction of 3-methoxy-2-hydroxybenzaldehyde (1) with dimedone (2) using water as solvent at room temperature. Subsequently, NaS or NaCl was added under reflux to obtain (R)-9-mercapto-5-methoxy-3,3-dimethyl-3,4-dihydro-2H-xanthen-1(9H)-one (5) and 9-chloro-3,4-dihydro-5-methoxy-3,3-dimethyl-2H-xanthen-1(9H)-one (6), respectively. The final reaction proceeded under reflux with water only to obtain 3,4-dihydro-9-hydroxy-5-methoxy-3,3-dimethyl-2H-xanthen-1(9H)-one (7). Compounds 5, 6 and 7 were selected due to their structural similarities to tacrine, which is one of the most effective AChE inhibitors for AD. The compounds were studied by nuclear magnetic resonance (NMR) to assign all chemical shifts and determine their three-dimensional structures. A parallel molecular modeling study was conducted to confirm the NMR results and obtain the energy, dipole moment, area, polar surface area (PSA) and volume of each compound. The PSA values indicated that the new compounds should be able to cross the blood-brain barrier. Compounds 5, 6 and 7 were then tested as inhibitors of human acetylcholinesterase (HuAChe) using docking experiments, and in vitro tests of the compounds as HuAChe inhibitors were performed using the Fig-NMR method with tacrine as a reference. The results confirmed that the new compounds are effective agents for the treatment of AD. Toxicity tests carried out using mice indicated very low toxicity. The findings suggest that the new compounds are better agents than tacrine for the treatment of AD.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85021633597&origin=inward; http://dx.doi.org/10.1039/c6ra27042e; http://xlink.rsc.org/?DOI=C6RA27042E; http://pubs.rsc.org/en/content/articlepdf/2017/RA/C6RA27042E; https://xlink.rsc.org/?DOI=C6RA27042E; https://dx.doi.org/10.1039/c6ra27042e; https://pubs.rsc.org/en/content/articlelanding/2017/ra/c6ra27042e
Royal Society of Chemistry (RSC)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know